Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab and Fianlimab in Clear Cell Renal Cell Carcinoma
NCT06699602Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in clear cell renal cell carcinoma (ccRCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2025; status: recruiting.
02
Drugs
fianlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06699602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699602.